<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A patient with a previous history of <z:e sem="disease" ids="C0677886" disease_type="Neoplastic Process" abbrv="EOC">epithelial ovarian cancer</z:e> presented to her physician with diffuse <z:mp ids='MP_0000702'>adenopathy</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>On subsequent evaluation, she was found to have a follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Work-up revealed an elevated serum CA-125 antigen level, raising the question of whether the <z:hpo ids='HP_0001939'>laboratory abnormality</z:hpo> represented evidence of recurrence of the original epithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The subsequent major decline in this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker following treatment directed to the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> provided strong support for the conclusion that the elevated CA-125 was secondary to this malignant process and not <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
</text></document>